KOWLOON BAY, Hong Kong
- July 29, 2020
-- Immunother Ltd is currently researching and developing therapies for inflammatory diseases and currently are trialing treatments at its Shenzhen facility and Edward Ho will oversee all operations and will bring his experiences to advance knowledge of various diseases, including its management and treatment.
Immunother Ltd's Director, Mr. Lin Zhang PhD commented on the appointment of Edward Ho saying "Edward brings extensive experience in clinical research and operations to Immunother Ltd and we are currently advancing our lead clinical trials through to phase 1 and 2 clinical trials. As we continue to progress the program, we will rely on Edward's operational expertise."
"Edward's experience, which includes leading clinical operations and driving multiple clinical programs at large pharmaceutical companies that ultimately led to product approvals. We are excited to add Edward to our team as we move toward initiating pivotal clinical studies and bringing solutions to target and treat various diseases," added Lin Zhang, Director of Immunother Ltd.
About Us - Immunother
Immunother Limited Company is a privately held Shenzhen-based preclinical stage biotechnology company focused on discovering and developing novel therapies for inflammatory diseases.http://www.immunother.com/About/index.html
Immunother Limited Company creates lasting value through pioneering research in the field of immunology which leads to new product concepts, product development, and finally to the licensing of those products and associated intellectual property.